BBEST Enzyme Therapy

About AMYRA Biotech

AMYRA Biotech is a private, pre-clinical stage biotech developing a novel enzyme therapy for celiac disease and non-celiac gluten sensitivity. Its core technology, the BBEST (Bread and Breakfast Enzyme Support Therapy) platform, aims to degrade immunogenic gluten peptides in the stomach before they trigger an immune response. The company is positioned to address a significant unmet medical need in a large and growing market, with its lead program advancing through preclinical development. As a private entity, its financial runway and future development milestones are likely dependent on securing further investment or partnerships.

Therapeutic Areas